trending Market Intelligence /marketintelligence/en/news-insights/trending/uqlktsoo3u4echxtcbpr-q2 content esgSubNav
In This List

EyeGate's eye drug not as effective as steroid treatment in late stage study

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


EyeGate's eye drug not as effective as steroid treatment in late stage study

EyeGate Pharmaceuticals Inc.'s EGP-437 drug was not as effective as a steroid medicine in treating inflammation of the middle layer of the eye, a late stage study showed.

The Waltham, Mass.-based specialty pharmaceutical company compared the safety and efficacy of EGP-437 with prednisolone acetate ophthalmic solution, a steroid treatment, in patients with noninfectious anterior segment uveitis.

Anterior uveitis is a condition characterized by inflammation in the front area of the eye, including the iris and the adjacent ciliary body. The inflamed iris causes the shedding of white blood cells into the anterior chamber.

The company found that the drug showed some clinical efficacy, but after 14 days of treatment, EGP-437 failed to work as well as the steroid treatment. EyeGate intends to review the data and determine strategic options for the drug going forward.

Eyegate President and CEO Stephen From said the company will now shift focus to key clinical trials for its ocular bandage gel product, which is intended to treat patients with corneal surface damage.